Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.44 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611470 | 1.00 | DGAT1 (0.44) | DGAT1CNR2RAB9ACYP1A2ATR | |
| SCHEMBL7616472 | 0.88 | HDAC3 (0.37) | DGAT1CNR2RAB9ACYP1A2NPC1 | |
| SCHEMBL7606823 | 0.88 | GAK (0.40) | CNR2RAB9ACYP1A2ATRNPC1 | |
| SCHEMBL7616464 | 0.88 | HDAC3 (0.37) | DGAT1CNR2RAB9ACYP1A2NPC1 | |
| SCHEMBL7606838 | 0.88 | GAK (0.40) | CNR2RAB9ACYP1A2ATRNPC1 | |
| SCHEMBL5429371 | 0.86 | DGAT1 (0.45) | DGAT1CNR2RAB9ACYP1A2 | |
| SCHEMBL5429367 | 0.86 | DGAT1 (0.45) | DGAT1CNR2RAB9ACYP1A2 | |
| SCHEMBL7611753 | 0.86 | FLT3 (0.46) | CNR2RAB9ACYP1A2NPC1 | |
| SCHEMBL7611744 | 0.86 | FLT3 (0.46) | CNR2RAB9ACYP1A2NPC1 | |
| SCHEMBL7609852 | 0.84 | RAB9A (0.41) | CNR2RAB9ACYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | claimed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | claimed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | DGAT1 4630/4885CNR2 4208/4885RAB9A 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.